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We have identified a homozygous mutation near the
carboxyl terminus of the insulin receptor (IR) a subunit
from a leprechaun patient, changing Asp707 into Ala.
Fibroblasts from this patient had no high affinity insu-
lin binding sites. To examine the effect of the mutation
on IR properties, the mutant IR was stably expressed in
Chinese hamster ovary cells. Western blot analysis and
metabolic labeling showed a normal processing of the
mutant receptor to a and b subunits. No increase in high
affinity insulin binding sites was observed on Chinese
hamster ovary cells expressing themutant receptor, and
also, affinity cross-linking of 125I-labeled insulin by di-
succinimidyl suberate to these cells failed to label the
mutant a subunit. Biotinylation of cell surface proteins
by biotin succinimidyl ester resulted in efficient biotin-
ylation of the mutant IR a and b subunits, showing its
presence on the cell surface. On solubilization of the
mutant insulin receptor in Triton X-100-containing buf-
fers, 125I-insulin was efficiently cross-linked to the re-
ceptor a subunit by disuccinimidyl suberate.
These studies demonstrate that Ala707 IR is normally
processed and transported to the cell surface and that
the mutation distorts the insulin binding site. Detergent
restores this site. This is an example of a naturally oc-
curring mutation in the insulin receptor that affects
insulin binding without affecting receptor transport
and processing. This mutation points to a major contri-
bution of the a subunit carboxyl terminus to insulin
binding.
Insulin induces mitogenic and metabolic responses in cells.
In addition, in muscle and adipose tissues, glucose transporters
become translocated to the plasma membrane (1). These re-
sponses require tyrosine kinase activity in the cytoplasmic tail
of the insulin receptor, which is activated on binding of insulin
(2, 3). The insulin receptor is synthesized as a proreceptor,
which after proteolytic cleavage into a and b subunits and
extensive glycosylation in the Golgi apparatus, appears pre-
dominantly as an a2b2 tetramer on the cell surface (4).
A number of naturally occurring mutations in the insulin
receptor have been found to associate with diseases of severe
insulin resistance (5). Missense mutations in the cytoplasmic
domain of the receptor are often seen in patients with type A
insulin resistance. These mutant receptors are processed to
a2b2 tetramers and transported to the cell surface. Usually
they retain their insulin binding properties. The impaired ac-
tivation of the receptor tyrosine kinase contributes to the de-
velopment of the syndrome of insulin resistance. Missense mu-
tations in the homozygous or compound heterozygous state in
the extracellular part of the receptor are often associated with
syndromes of extreme insulin resistance such as lepre-
chaunism (MIM 246200) or Rabson Mendenhall syndrome
(MIM 262190) (5, 6). Many of the missense mutations involved
lead to a loss of high affinity insulin binding sites on cells.
These mutations are predicted to affect the folding of the a
subunit and the formation of correct disulfide bonds. As a
result, the proreceptor is retained in the endoplasmic reticu-
lum, and no receptors are transported to the cell surface (7, 8).
Another situation that leads to a decreased number of func-
tional receptors on the cell surface is represented by the natu-
rally occurring mutation Glu460. This receptor undergoes en-
hanced internalization and degradation on binding of insulin
(9).
We have recently encountered leprechaun patient HO. This
patient was found to have a mutation in the insulin receptor,
which interferes with insulin binding, probably by a direct
effect on the structure of the insulin binding site.
EXPERIMENTAL PROCEDURES
Reagents, Antibodies, and General Procedures—Cultures of fibro-
blasts and CHO1 cell lines were as described (7). Taq polymerase was
from Perkin-Elmer; other enzymes for DNA manipulation were from
New England Biolabs, Promega, and Boehringer Mannheim. Other
reagents were of analytical grade. Monoiodo-A14 insulin (2000 Ci/
mmol), a monoclonal antibody against the insulin receptor and biotin
succinimidyl ester were from Amersham Corp. Protein A-Sepharose
and wheat germ agglutinin-Sepharose were from Pharmacia Biotech,
Inc. Disuccinimidyl suberate was from Pierce. Preparation of polyclonal
antibodies against the insulin receptor, isolation of DNA from cultured
fibroblasts, and amplification of the coding parts of exons 1–22 of the
insulin receptor were described previously (7). Monoclonal antiphospho-
tyrosine antibody (PY20) was from Upstate Biotechnology, Inc. Glyco-
protein from CHO cells was isolated by chromatography on wheat germ
agglutinin-Sepharose, as described previously, using Hepes-containing
buffers instead of Tris. Protein content was determined using the Bio-
Rad DC protein assay kit.
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Patient—The child, a boy, was born from first cousin parents. He had
the phenotypic characteristics of leprechaunism, including marked lack
of adipose tissues, prominent eyes and lips, wrinkled loose skin, acan-
thosis nigricans, abdominal distention, prominent nipples, and large
phallus. Insulin levels varied during the day between 237 and 424
milliunits/liter (normal value, ,25 milliunits/liter). The child died at
the age of 8 months.
DNA Sequencing—The exons for the insulin receptor gene were
amplified using DNA from the patient’s fibroblasts (10). Amplified
fragments were purified on low melting point agarose and sequenced
using the DNA sequencing kit from Pharmacia as described previously
(7).
Construction of Insulin Receptor (Ala707) cDNA in the Expression
Vector SV40HIR—A DNA fragment containing exon 10 was prepared
by polymerase chain reaction from the patient’s DNA (10). This frag-
ment was digested by DraIII and BsmI and ligated into a plasmid
(pMK5) containing the BamHI-HincII fragment of the human IR (nu-
cleotides 1926–3187; numbering according to Ref. 2). An XhoI-XhoI
fragment (nucleotides 2091–3068) was isolated and exchanged for the
corresponding XhoI-XhoI fragment in the WT IR cDNA, cloned in the
pUC12 vector. A BstEII-BstEII fragment (nucleotides 1836–4321) was
exchanged for the corresponding fragment in the expression vector
carrying the WT IR cDNA, driven by the SV40 promotor (11). The
correct structure of the exchanged fragment was confirmed by DNA
sequencing.
Transfection of CHO Cells and Selection of Clones Expressing Ala707
IR—Construction of clonal CHO cell lines expressing mutant insulin
receptors was done by using lipofectamine (Life Technologies, Inc.),
and clones expressing insulin receptors were identified as described
previously (7).
Cell Surface Labeling—Cells were grown to confluency in 3-cm
dishes and subsequently washed three times with 1 ml of 10 mM sodium
phosphate, pH 8.6, 150 mM NaCl, 0.1 mM MgCl2, and 0.1 mM CaCl2.
Cells were kept in 1 ml of this buffer. Biotin succinimide ester (in dry
dimethyl formamide) was added to the cells according to the instruc-
tions provided by the manufacturer (Amersham Corp.). Incubation was
for 1 h at room temperature. Cells were washed, lysed in 0.5 ml of
ice-cold lysis buffer (1% Nonidet P-40, 20 mM Tris-HCl, pH 7.60, 0.1 mM
EDTA, 0.1 mM phenylmethylsulfonyl fluoride, Trasylol, and soybean
trypsin inhibitor; 1 mg/ml each). Cells were kept at 0 °C for 30 min, and
the lysate was centrifuged for 10 min at 14,000 rpm to remove nuclei.
The supernatant was diluted to 1.5 ml with immune precipitation
buffer (0.1% Nonidet P-40, 20 mM Tris-HCl, pH 7.60, 150 mM NaCl, 0.1
mM phenylmethylsulfonyl fluoride, Trasylol, and soybean trypsin inhib-
itor; 1 mg/ml each), and 750 ml was subjected to immune precipitation
with polyclonal anti-IR (5 ml) or monoclonal anti-IR (3 ml). After incu-
bation for 16 h at 4 °C, immune complexes were allowed to bind to
protein A-Sepharose beads for 30 min at 4 °C. The beads were washed
five times with immune precipitation buffer, and bound proteins were
eluted by SDS sample buffer. The proteins were separated on a 7%
SDS-polyacrylamide gel and blotted onto a polyvinylidene difluoride
membrane, which was probed with avidin-peroxidase conjugate accord-
ing to the protocol provided by the manufacturer (Amersham). Proteins
were visualized by ECL (Amersham).
Cross-linking of Monoiodo-A14 Insulin to Insulin Receptors—Cells
were grown to confluency in 3-cm dishes and subsequently washed with
phosphate-buffered saline, pH 7.8, containing 1 mg/ml bovine serum
albumin. Cells were kept in 300 ml of this buffer, and 125I-monoiodo-A14
insulin (2000 Ci/mmol) was added to a concentration of 100 pM. Incu-
bation was for 1 h at room temperature. Subsequently, the mixture was
cooled to 0 °C; disuccinimidyl suberate (50 mM in Me2SO) was added to
a final concentration of 0.2 mM; and incubation was continued for 20
min. The mixture was made 50 mM in Tris-HCl, pH 7.8, and cells were
washed with 20 mM Tris-HCl, pH 7.6, and 150 mM NaCl. Cell lysis and
immune precipitations were as described under “Cell Surface Labeling.”
Cross-linking to partially purified insulin receptors was performed
using glycoprotein (2 mg) in 15 ml of 10 mM Hepes, 5 mM MgCl2, and 0.3
MN-acetylglucosamine. 125I-Insulin was added to a concentration of 700
pM, and incubation was for 16 h at 0 °C. Cross-linking by disuccinimidyl
suberate and immune precipitation was performed as described above.
Analysis of Insulin Receptor Expression and Tyr Phosphorylation
Status by Western Blot—Cells were grown to confluency and placed for
16 h in Dulbecco’s modified Eagle’s medium, containing 1% bovine
serum albumin, to bring them in a quiescent state. Cells were incubated
for 15 min in this medium, containing, in addition, 1 mM insulin, and
lysed in SDS sample buffer. Lysate (25 mg of protein) was electrophore-
sed on SDS-polyacrylamide gels and blotted on polyvinylidene difluo-
ride membranes. Visualization of the insulin receptor was achieved
using a polyclonal peptide antiserum, raised in rabbits, recognizing
amino acids 1328–1343 at the carboxyl terminus of the receptor b chain
and peroxidase-conjugated anti-rabbit IgG. Tyrosine-phosphorylated
proteins were visualized using peroxidase-conjugated PY20 antiserum.
Detection was by ECL.
In another set of experiments, cells were incubated in isotonic auto-
phosphorylation buffer (20 mM Tris-HCl, pH 7.60, 140 mM NaCl, 5 mM
MnCl2, and 25 mM ATP) in the absence or presence of 1 mM insulin for
5 min at 37 °C. Cells were lysed either by addition of SDS or by addition
of Triton X-100 to a 1% final concentration. Subsequently, the lysate
was analyzed by Western blot for phosphotyrosine content using the
monoclonal antibody PY20.
RESULTS
Insulin Binding to the Patient’s Fibroblasts—Insulin binding
to cultured fibroblasts from leprechaun patient HO and to
fibroblasts from a healthy control is visualized in Fig. 1. For
comparison, results of an insulin binding experiment using
fibroblasts from leprechaun G are included. Leprechaun G was
described by us previously (12) and is homozygous for a muta-
tion in the insulin receptor, changing Leu233 into Pro. High
affinity insulin binding sites were nearly absent on fibroblasts
from patient HO and leprechaun G. The absence of high affin-
ity insulin binding sites is a characteristic property of fibro-
blasts from most patients with leprechaunism.
DNA Sequence Analysis—DNA was isolated from cultured
fibroblasts of patient HO and from peripheral blood of both
parents. Exons encoding the insulin receptor were amplified
(10) and analyzed by DNA sequence analysis, directly on am-
plified DNA. Apart from known polymorphisms, the patient
exhibited an additional mutation in homozygous form, which
leads to replacement of the Asp codon GAT at position 707 by
the codon GCT for Ala. Both parents were found to be heterozy-
FIG. 1. Binding of 125I-insulin to cul-
tured fibroblasts. Hatched bars, total
binding; open bars, binding in the pres-
ence of 1 mM nonradioactive insulin. Bind-
ing values are to 106 fibroblasts.
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gous for this mutation. No other mutations were detected in the
coding or consensus sequences at the splice junctions. Analysis
by polymerase chain reaction of cDNA prepared from the pa-
tient’s fibroblasts and from fibroblasts of a control individual
indicated approximately normal levels of IR mRNA (not
shown).
Expression of Ala707 IR in CHO Cells—To examine the effect
of the mutation on properties of the insulin receptor, we ex-
pressed the mutant receptor in CHO cells. IR cDNA constructs
carrying the mutation were ligated into an SV40-driven expres-
sion vector carrying the neo resistance gene (11). CHO cells
were transfected with the construct and, G418-resistant cell
lines were selected. In addition, we transfected CHO cells by
this vector carrying cDNA for the WT IR. Expression of the IR
protein was monitored by Western blot analysis using a poly-
clonal antibody against a peptide sequence (amino acids 1330–
1343) in the carboxyl-terminal region of the receptor b chain.
Clonal CHO cell lines, transfected by Ala707 IR cDNA, showed
expression of the b chain. Expression levels showed some vari-
ations in different clones. Fig. 2 represents the data on a clone
with an average expression level. In addition, the data in Fig.
2 include parental CHO cells and transfected CHO cells ex-
pressing WT IRs. The latter cell line expresses approximately
250,000 high affinity insulin binding sites per cell, based on
Scatchard analysis. We also included in the Western blot anal-
ysis CHO cells expressing the transport-defective receptor
Arg31 IR, originating from leprechaun H (7). We showed previ-
ously that this transport-defective receptor is retained in the
endoplasmic reticulum as a proreceptor and not processed into
a and b subunits. It is obvious that Ala707 IR is proteolytically
processed like WT IRs, as judged from the predominant stain-
ing of the b subunit on the Western blot. In contrast, the
transport-defective receptor Arg31 IR from leprechaun H only
exhibits staining of the proreceptor by the antibody against the
peptide epitope on the b subunit carboxyl terminus.
Data obtained by metabolic labeling of these CHO cell lines
by [35S]methionine and immune precipitation of the insulin
receptor followed by analysis of the immune precipitate by
SDS-polyacrylamide gel electrophoresis and autoradiography
confirmed that Ala707 IR is processed into a and b subunits,
like WT IRs. These data are presented in Fig. 3. The electro-
phoretic mobilities of a and b subunits from WT and Ala707 IRs
were similar, suggesting a similar degree of glycosylation. This
notion is corroborated by the normal mobilities of mutant a
subunits, visualized by biotinylation (Fig. 4) and iodination
(Fig. 6).
Biotinylation of Cell Surface Proteins—To examine whether
Ala707 IR is transported to the surface of cells, we labeled cell
surface proteins of the various CHO cell lines with biotin suc-
cinimidyl ester, a protein reagent that couples biotin moieties
to exposed lysine residues of proteins on the cell surface. Pa-
rental CHO cells, and CHO cells expressing WT and Ala707 IRs,
respectively, were incubated with the reagent. Subsequently,
cells were lysed, and insulin receptors were immune precipi-
tated with a polyclonal antibody against the human insulin
receptor. The immune precipitates were electrophoresed on
SDS-polyacrylamide gel and transferred to polyvinylidene di-
fluoride membranes. Biotinylated proteins were visualized by
peroxidase-conjugated streptavidin and ECL (Fig. 4). CHO
cells expressing the WT receptor and Ala707 IR gave a similar
picture of a and b chain labeling, although when the ratio of a/b
subunit labeling was considered, the mutant receptor tended to
show a higher ratio of a/b chain labeling. Using parental CHO
cells, no signal was obtained at these exposure times. These
findings indicate that the Ala707 mutant is transported to the
cell surface to a similar extent as WT IRs.
The possibility exists that Ala707 IR undergoes a rapid inter-
nalization and degradation on incubation with insulin. Such a
situation could also deplete the cell surface of insulin receptors,
thereby leading to a state of insulin resistance. This situation is
exhibited by the mutant insulin receptor Glu460 IR. This par-
ticular mutant originates from a leprechaun patient (8). As this
mutation results in a decreased rate of the dissociation of the
receptor-ligand complex, the presence of insulin leads to en-
hanced internalization and degradation. To examine whether
Ala707 IR exhibits pronounced insulin-induced receptor inter-
nalization, CHO cells expressing the mutant receptor were
incubated in medium containing 1 mM insulin for up to 60 min
at 37 °C, followed by biotinylation of the cell surface proteins
and analysis of the mutant receptor for biotinylation, As a
control, CHO cells expressing WT IRs were used. Fig. 5 shows
that incubation of mutant receptor-expressing cells with insu-
FIG. 2. Analysis of IR expression in transfected CHO cells by
Western blot. CHO cells were transfected by cDNA encoding the WT
IR, Ala707 IR, Arg31 IR, or expression vector alone (control). Clonal cell
lines were isolated, and total cell lysate was analyzed by Western
blotting using an antiserum recognizing a peptide epitope on the car-
boxyl terminus of the b chain. Arrows, positions of the b subunit (95
kDa) and the proreceptor (200 kDa).
FIG. 3. Analysis of IR expression in transfected CHO cells by
metabolic labeling and autoradiography. CHO cells were trans-
fected by cDNA encoding the WT or Ala707 IR or mock transfected
(control). Cells were grown in medium containing [35S]methionine, fol-
lowed by lysis of the cells and immune precipitation of the insulin
receptor. The immune precipitated receptor was subjected to electro-
phoresis on SDS-polyacrylamide gels, and the gels were analyzed by
autoradiography.
FIG. 4. Biotinylation of cell surface proteins. CHO cells express-
ing WT or Ala707 IR and control CHO cells were incubated with biotin
succinimidyl ester. After lysing the cells, insulin receptors were im-
mune precipitated by a polyclonal antibody, and the immune precipi-
tate was subjected to Western blot analysis. Visualization of biotinyla-
tion was by streptavidin-peroxidase conjugate and ECL.
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lin does not markedly decrease the level of receptor biotinyla-
tion, indicating that a situation of enhanced insulin-induced
receptor internalization does not take place. In the case of WT
IR, incubation with insulin decreases the ratio of a subunit
labeling over b subunit labeling. This lower level of a subunit
labeling may result from binding insulin to the WT a subunit,
thereby reducing the number of accessible Lys residues on the
subunit for biotinylation or by inducing a conformational
change. The mutant receptor, which does not show insulin
binding, does not exhibit a decreased ratio of a/b subunit la-
beling on addition of insulin.
When b subunit labeling is considered in multiple experi-
ments, an approximately 25% decrease is seen at 60 min of
incubation time in the case of cells expressing WT IRs, reflect-
ing the degree of internalization. No significant decrease is
seen in the case of the receptor mutant.
Insulin Binding and Affinity Cross-linking—The various
CHO clonal lines overexpressing the Ala707 IRs showed no
increase in the level of high affinity binding of 125I-insulin
when compared with the parent CHO cell line (Table I). These
binding experiments were performed at a tracer concentration
of 30 pM 125I-monoiodo-A14 insulin. We subsequently per-
formed insulin binding and 125I-insulin cross-linking experi-
ments using insulin receptors partially purified from trans-
fected CHO cells by chromatography on wheat germ
agglutinin-Sepharose. In those experiments, insulin receptors
are solubilized in a Hepes buffer containing 0.1% Triton X-100.
It was found that in such a buffer 125I-insulin (700 pM) in the
presence of the protein cross-linker disuccinimidyl suberate
was efficiently cross-linked to the a subunit of both WT and
Ala707 IR. Judged from the degree of a subunit labeling, the
efficiency of cross-linking seems similar (Fig. 6).
We also carried out cross-linking of 125I-insulin to intact
CHO cells either expressingWT or Ala707 IRs by disuccinimidyl
suberate. Those experiments only showed labeling of the insu-
lin receptor a subunit in the case of CHO cells expressing WT
IR. Cells expressing the mutant receptor showed no detectable
affinity labeling of the a subunit of the mutant receptor (not
shown). These experiments indicate that in the case of intact
cells, no transient interaction between insulin and Ala707 IR
occurs, e.g. due to a high Koff rate. Only when detergent-solu-
bilized insulin receptors were used, as present in the glycopro-
tein fraction, a detectable interaction between the mutant in-
sulin receptor and insulin occurs.
Insulin-induced Autophosphorylation of Ala707 IR—Initially
we examined whether insulin was able to induce autophospho-
rylation of the mutant receptor on transfected CHO cells. Cells
expressing mutant IRs were incubated for 5 min in medium
containing 1 mM insulin, followed by removal of insulin by
washing the cells with ice-cold phosphate-buffered saline. Sub-
sequently, cells were lysed, the insulin receptor was immune
precipitated, and the immune precipitate was examined by
Western blotting for Tyr phosphorylation. As a control experi-
ment, transfected CHO cells expressing a similar level of WT
IRs were included. Incubation of cells expressing the WT IR
showed a pronounced increase in Tyr phosphorylation of the b
subunit, whereas cells expressing Ala707 IR showed no detect-
able b subunit Tyr phosphorylation (Fig. 7). When the phos-
photyrosine phosphatase inhibitor phenyl arsenic oxide was
included, no b subunit labeling was detected in the case of
Ala707 IR (Fig. 7). Also, when cells were directly lysed in SDS
sample buffer after incubation with insulin, Western blot anal-
ysis did not show any increase in phosphotyrosine labeling of
cellular proteins in the case of the mutant receptor (not shown).
These observations argue against a situation in which the
mutant receptor is highly susceptible to dephosphorylation by
a phosphotyrosine phosphatase.
We also examined insulin-induced receptor autophosphoryl-
ation using partially purified insulin receptors, obtained by
chromatography on wheat germ agglutinin-Sepharose. Insulin
receptors isolated in this way are solubilized in a buffer con-
taining 0.1% Triton X-100. Insulin (1 mM) was found to induce
b chain phosphorylation in the case of WT and mutant recep-
tors. Absolute levels of phosphate incorporation were approxi-
mately 15% lower in mutant receptors compared with WT IRs,
although this difference did not reach statistical significance.
When a dose-response relationship was determined, the ED50
was the same for WT and mutant receptors. The only difference
that showed statistical significance was a lower level of phos-
phate incorporation in mutant receptors at low insulin concen-
trations (Fig. 8).
To further examine the requirement for Triton X-100 for
insulin-induced receptor autophosphorylation and to exclude
the possibility that other components of the glycoprotein buffer,
such as N-acetylglucosamine, are responsible for the restora-
tion of the interaction between Ala707 IR and insulin, in a
parallel experiment we incubated CHO cells expressing WT
and mutant IRs for 5 min with insulin. This incubation oc-
curred in an isotonic buffer, containing 1 mM insulin, ATP, and
MnCl2, reagents required for in vitro autophosphorylation. As
a control, cells were incubated in this buffer without insulin.
Receptor autophosphorylation was analyzed by lysing the cells
by addition of SDS sample buffer, and the lysate was analyzed
for the presence of Tyr-phosphorylated proteins by Western
FIG. 5. The effect of insulin on internalization of insulin recep-
tors. CHO cells expressing WT or Ala707 IR were incubated for the
indicated time points (min) in medium with 1 mM insulin. Subsequently,
cell surface proteins were biotinylated, and insulin receptor biotinyla-
tion was assessed by Western blot, as described in the legend of Fig. 4.
TABLE I
Specific binding of insulin to various CHO cell lines
Cell line Bindinga
10217mol/106 cells
Parental CHO 2.2 6 0.2
CHO Ala707 IRb 2.3 6 0.3
CHO WT IRb 247 6 28
a Values are mean 6 S.D.
b Western blot data indicate similar levels of insulin receptor expres-
sion.
FIG. 6. Cross-linking of 125I-insulin to the insulin receptor
a-subunit. Glycoprotein was prepared from CHO cells expressing WT
or Ala707 IR. Glycoprotein was incubated with 700 pM 125I-insulin alone
(2) or together with 1 mM nonradioactive insulin (1). Cross-linking to
the a subunit was by disuccinimidyl suberate. Subsequently, proteins
were electrophoresed on SDS-polyacrylamide gels and visualized by
autoradiography.
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blot. Fig. 9 shows that under these conditions, insulin is capa-
ble of inducing receptor autophosphorylation only in CHO cells
expressing WT IRs. However, when cells were incubated in the
isotonic autophosphorylation buffer and Triton X-100 was
added to lyse the cells, insulin induced a marked autophospho-
rylation of the mutant insulin receptor.
DISCUSSION
Leprechaun patient HO is homozygous for a mutation in the
insulin receptor, which replaces Asp707 by Ala. This mutant
receptor is normally processed into a and b subunits and trans-
ported to the cell surface. In the a chain, the proper positioning
of Cys residues is essential for correct disulfide bond formation
and for the formation of functional insulin receptors, which can
be transported to the cell surface. A number of mutations in the
a chain, found in patients with leprechaunism or Rabson Men-
denhall syndrome, lead to transport-defective receptors, which
are retained in the endoplasmic reticulum. Those mutations
often involve amino acid residues near Cys residues, and the
nature of the amino acid substitution is such that it is likely
that they affect the folding of the polypeptide chain (5). Residue
707 is located near the carboxyl terminus of the a chain. This
region has a high probability of existing in an a helical confor-
mation. No Cys residues involved in disulfide bond formation
are found in this part of the receptor. Because Ala707 IR is
transported to the cell surface, it is expected that the mutation
has no major effect on the overall folding of the a subunit. This
situation is corroborated by protein structure predictions,
which indicate that substituting Ala for Asp has no major effect
on the probability of the carboxyl terminus adopting an a
helical configuration. Because of the smaller side chain of Ala
compared with Asp, the helix may become more flexible at that
site.
Despite the predicted absence of a major effect on protein
folding, Ala707 IR is unable to bind insulin when expressed on
cells. The absence of insulin binding to cells expressing the
mutant insulin receptor is not the result of enhanced internal-
ization and receptor degradation, a situation seen in case of the
Glu460 mutant (9). We conclude that the loss of insulin binding
to cells expressing Ala707 IR is due to a direct effect of the
mutation on the process of insulin binding. This loss of binding
may, in principle, result from an essential contribution of
Asp707 to the interaction of the receptor with insulin or to a
conformational change induced by Ala707, which affects the
structure of the insulin binding pocket.
When insulin binding to Ala707 IR is determined in the
presence of Triton X-100, binding of insulin to the mutant
receptor is seen, and this binding induces receptor autophos-
phorylation. The dose-response relationship for insulin-in-
duced receptor autophosphorylation shows an unchanged ED50
and a slightly, but significantly, lower autophosphorylation at
low insulin concentrations. These observations indicate that in
the presence of detergent, the mutation has a minor effect on
the kinetics of insulin binding and that Asp707 does not provide
interactions that are essential for insulin binding. Rather, the
data suggest that the introduction of Ala707 induces a change in
the positioning of the carboxyl-terminal a helix, which prevents
insulin from binding when the receptor is on the cell surface.
Detergent somehow is able to restore insulin binding. It may do
so by making the structure of the carboxyl-terminal part of the
receptor a subunit more flexible, thereby allowing the carboxyl
terminus of Ala707 IR to adopt a position that allows insulin to
bind. Another possibility is that the mutant receptor has
gained the ability to bind to another protein, which prevents
insulin from binding. We think that this situation is unlikely,
because we do not observe coprecipitating proteins in insulin
receptor immune precipitates frommetabolically labeled Ala707
IR-expressing cells that are absent in cells expressing WT IRs.
Previously, sites on the insulin receptor that are important
for the binding of insulin were identified in the NH2-terminal
region, especially Phe89 (13–15), the cysteine-rich region (16–
18), and the region encoded by exons 6 and 7 (9, 19, 20). Also,
an important contribution of Ser323 to the formation of a high
affinity insulin binding site on the receptor has been detected
by the study of an insulin-resistant patient. Substituting Leu
for Ser323 leads to a severe impairment in insulin binding
without significantly altering the processing or cell surface
expression of the receptor (21).
FIG. 9. Effect of Triton X-100 on insulin-induced receptor b
chain autophosphorylation. CHO cells expressing WT or Ala707 IR
were incubated in isotonic autophosphorylation medium without (2) or
with (1) insulin, and incubation was for 5 min. Subsequently, Triton
X-100 was added to indicated cells (1) to a concentration of 1%. Incu-
bation was continued for another 3 min. Subsequently, SDS sample
buffer was added, and the lysate was subjected to Western blot analysis
and stained with antiphosphotyrosine antibodies. Visualization was by
ECL. The position of the insulin receptor b chain is presented.
FIG. 7. Insulin-induced Tyr phosphorylation of insulin recep-
tors. CHO cells expressing WT or Ala707 IR were kept quiescent or
incubated with 1 mM insulin for 10 min. Cells were lysed, and IRs were
immune precipitated by a monoclonal antibody. The immune precipi-
tate was subjected to Western blot analysis, and visualization of Tyr-
phosphorylated protein was by monoclonal antiphosphotyrosine anti-
body and ECL. To enhance a possibly low level of Tyr phosphorylation
of the insulin receptor b chain, phenylarsenic oxide (PAO, 1) was
included in some experiments.
FIG. 8. Insulin-induced b chain phosphorylation using par-
tially purified insulin receptors. Glycoprotein was prepared from
CHO cells expressing WT or Ala707 IR. Glycoprotein was incubated with
increasing concentrations of insulin for 30 min, followed by addition of
[g-32P]ATP to induce autophosphorylation. Proteins were electrophore-
sed on SDS-polyacrylamide gels, and incorporation of 32P in the insulin
receptor b chain was quantitated by PhosphorImager analysis. Incor-
poration is expressed as percentage of maximum incorporation. l, WT
IRs; E, Ala707 IRs. Values are averages of a triplicate experiment. Bars,
S.D.
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Subsequently, another site on the receptor has been identi-
fied that may contribute to insulin binding. Ultraviolet light-
induced cross-linking of B25 azidophenylalanine insuline was
found to occur in a peptide comprising residues 704–718 (22).
This finding suggests a direct interaction between insulin and
the carboxyl terminus of the receptor. Also in agreement with
a role of the carboxyl terminus in insulin binding is the obser-
vation that a secreted form of the extracellular part of the
insulin receptor, in which the carboxyl terminus of the a sub-
unit is lacking, has a low affinity for insulin (23).
The region comprising amino acids 700–718 of the insulin
receptor has a high probability to adapt an a helical conforma-
tion. As we see a complete loss of insulin binding to the mutant
receptor in the absence of detergent, whereas addition of de-
tergent restores binding, it is likely that the precise positioning
of the carboxyl terminus is essential to enable binding of insu-
lin. In case of Ala707 IR, this positioning may be somewhat
changed, either due to an increased flexibility because of an Ala
residue at 707, or because Asp stabilizes the spatial positioning
of the a helix in a conformation that allows binding of insulin.
Somehow, detergent is able to restore the correct spatial posi-
tioning of the carboxyl terminus of the a chain, thereby restor-
ing the insulin binding site and insulin-induced receptor auto-
phosphorylation. Although the precise mechanism by which
Ala707 induces a complete loss of insulin binding is not known,
our data indicate that the carboxyl terminus of the a subunit
provides an essential contribution to the process of insulin
binding. Besides, our results show that solubilization by deter-
gent can markedly affect the interpretation of data on mutated
receptors when insulin binding characteristics are considered.
Other evidence suggesting a contribution of amino acid res-
idues in the carboxyl terminus of the a subunit to the binding
of insulin comes from insulin binding studies of proreceptors.
When mutations are present in the tetrabasic processing site at
the junction of a and b subunits, proreceptors are generated,
which appear on the cell surface (24). It was found that prore-
ceptors without exon 11 have markedly reduced insulin binding
compared with proreceptors with exon 11, which bind insulin
with near normal affinity. Cleavage of proreceptors without
exon 11 into a and b subunits markedly restored insulin bind-
ing. These findings suggest that the presence or absence of 12
amino acids encoded by exon 11 affects the folding and/or
conformation of the a subunit carboxyl-terminal region in the
proreceptor to confer altered binding of insulin. In the absence
of exon 11, this region is in a strained conformation that dis-
rupts the insulin binding site. Proteolytic cleavage at the a-b
junction releases this constraint (25).
After completion of the manuscript, a publication appeared
describing alanine-scanning mutagenesis of carboxyl-terminal
amino acids in the insulin receptor a subunit (26). This study
included the replacement of Asp707 by Ala. The results show
that when a secreted form of the a subunit is examined for
insulin binding, replacement of Asp707 by Ala did not affect
insulin binding properties. Replacements of several other
amino acid residues in the carboxyl-terminal region by Ala did
affect insulin binding. These results support our conclusion
that Asp707 as such is not essential for insulin binding when
receptors are in the solubilized state. Rather, when the insulin
receptor is present on the cell surface, Asp707 is essential in
keeping the carboxyl-terminal tail in a spatial conformation,
which allows insulin to bind. Ala707 IR represents the first
naturally occurring missense mutation in the carboxyl-termi-
nal part of the insulin receptor a subunit that affects binding of
insulin in the absence of an effect on receptor processing or
transport.
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